proteolytically derived endogenous angioinhibitors originating from the extracellular matrixproteolytically派生内生angioinhibitors来自细胞外基质.pdfVIP

Pharmaceuticals 2011, 4, 1551-1577; doi:10.3390/ph4121551 OPEN ACCESS Pharmaceuticals ISSN 1424-8247 /journal/pharmaceuticals Review Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix Chandra Shekhar Boosani 1 and Yakkanti A. Sudhakar 1,2,* 1 Cell Signaling, Retinal and Tumor Angiogenesis Laboratory, Department of Genetics, Boys Town National Research Hospital, Omaha, NE 68131, USA; E-Mail: ChandraShekhar.Boosani@ 2 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA * Author to whom correspondence should be addressed; E-Mail: Sudhakar.Yakkanti@; Tel.: +1-402-498-6681; Fax: +1-402-498-6331. Received: 14 October 2011; in revised form: 24 November 2011 / Accepted: 25 November 2011 / Published: 2 December 2011 Abstract: Angiogenesis, a neovascularization process induced from the existing parent blood vessels, is a prerequisite for many physiological and pathological conditions. Under physiological conditions it is regulated by a balance between endogenous angioinhibitors and angioactivators, and an imbalance between them would lead to pathological conditions such as cancer, age-related macular degeneration (AMD), diabetic retinopathy, cardiovascular diseases, etc. Several proteolytically generated endogenous molecules have been identified which exhibit angioinhibition and/or antitumor activities. These angioinhibitors interact with endothelial and tumor cells by binding to distinct integrins and